Humira (adalimumab) / AbbVie 
Welcome,         Profile    Billing    Logout  
 200 Diseases   176 Trials   176 Trials   21928 News 


12345678910111213...237238»
  • ||||||||||  Retrospective data, Review, Journal:  Comparative Efficacy of all Available Pharmaceutical Therapies for Moderate to Severe Crohn's Disease: A Systematic Review and Network Meta-Analysis. (Pubmed Central) -  Oct 27, 2025   
    In biologic-naive patients, adalimumab (high induction regimen) had the highest SUCRA ranking for induction of clinical remission, and infliximab/azathioprine combination therapy had the highest SUCRA ranking for maintenance of remission...Adverse event related discontinuation was numerically highest for methotrexate, azathioprine and upadacitinib...Differences in relative risks were small and confidence intervals overlapping. Findings show that conventional therapies remain important in the treatment algorithm for CD patients.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Modulation of Antibody Glycosylation in Chinese Hamster Ovary Cells: Experimental and Computational Analyses Provide Mechanistic Insights. (Pubmed Central) -  Oct 27, 2025   
    Here, we evaluated the glycan distribution of CHO-K1 clones producing adalimumab, a biosimilar version of the anti-TNF antibody Humira...We modeled the glycosylation pathways using a dynamic mathematical model to elucidate the mechanisms by which high mannose glycans increased and to develop a more predictive approach to culture modulation. Modeling results suggest that the concentration of uridine triphosphate (UTP), a component of activated sugars, is limiting and that increased uridine diphosphate (UDP)-galactose results in decreased UDP-N-acetylglucosamine, limiting complex glycan synthesis.
  • ||||||||||  Journal, Adverse events:  Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects. (Pubmed Central) -  Oct 27, 2025   
    Changes in SomaSignalTM proteomic tests over time in response to treatment were assessed in the EXSCEL (baseline vs 1 year; once-weekly exenatide (EQW) (n) = 1812 vs control (n) = 1787), SUGAR-DM-HF (baseline vs 12 weeks and 36 weeks; empagliflozin (n) = 45 vs control (n) = 52), AMPLE (baseline vs 85 days and 1 year; abatacept (n) = 210, adalimumab (n) = 222), and PRADA (baseline vs 7-10 days and 3 months, n = 120) trial...In contrast, anthracycline treatment led to significant increases in heart failure mortality risk (P ? 0.001) and cardiovascular risk (P =
  • ||||||||||  Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
    Journal:  Clinical Utility and Accuracy of Point-of-Care Testing for Anti-TNF Drug Monitoring and Loss of Response. (Pubmed Central) -  Oct 27, 2025   
    Intestinal ultrasound and MRI are effective modalities for monitoring the treatment response in patients with stricturing Crohn's disease (STRIDENT Drug Therapy Study: NCT03220841). Serum ADL and IFX POCT concentrations are comparable to ELISA and associated with LOR, indicating its clinical utility.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
    Journal, Adverse events:  Drug-induced cough risk: A pharmacovigilance study of FDA adverse event reporting system database. (Pubmed Central) -  Oct 26, 2025   
    This study is the first to systematically reveal the strength of association and baseline characteristics between multiple categories of drugs and the risk of cough, confirming the high efficiency and sensitivity of the FAERS database in pharmacovigilance. The findings of this study provide an important basis for drug risk assessment and clinical intervention.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Review, Journal:  New Methods in Dry Eye Treatment: Platelet-Rich Plasma. (Pubmed Central) -  Oct 24, 2025   
    Nonsteroidal anti-inflammatory drugs and tumor necrosis factor-alpha inhibitors, such as adalimumab, are increasingly used to manage severe cases of DED, showing efficacy in reducing symptoms and improving ocular surface integrity...Moreover, the increasing application of autologous serum and plasma rich in growth factors for the treatment of DED is substantiated by data indicating their capacity to enhance corneal epithelialization and mitigate DE symptoms. This review highlights the increasing significance of new therapeutic modalities, such as PRP, as essential for controlling DED, offering effective alternatives with improved clinical results.
  • ||||||||||  Remicade (infliximab) / J&J, colchicine / Generic mfg., Humira (adalimumab) / AbbVie
    Journal:  Epidemiological and Clinical Insights into Beh (Pubmed Central) -  Oct 22, 2025   
    This nationwide analysis highlighted sex-based differences in clinical features and found that BD continues to substantially affect quality of life. The widespread use of biologics suggests a shift in therapeutic strategies.
  • ||||||||||  Journal:  Case Report: Novel IL10RB variant causing very early onset-inflammatory bowel disease. (Pubmed Central) -  Oct 22, 2025   
    Standard biologic therapies (infliximab and adalimumab) were trialed in the second year of life without improvement...The patient's condition was partially controlled with anakinra (IL-1 receptor antagonist) as a bridge therapy...This case highlights the diagnostic and therapeutic challenges of IL-10R deficiency-related VEO-IBD. It also underscores the importance of early recognition of monogenic causes of IBD, use of interim immunomodulatory therapies, and the need for optimal timing and donor selection for HSCT.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Alkaline phosphatase-responsive hydrogel for efficient management of autoimmune intraocular inflammation. (Pubmed Central) -  Oct 19, 2025   
    This DexP hydrogel serves as a sustained-release depot for adalimumab (ADA), enabling synergetic AU therapy through a simple combination of aqueous DexP and ADA solutions with calcium chloride under mild conditions, which facilitates controlled release of both therapeutics in an ALP-responsive manner...Furthermore, the intravitreal administration of ADA@DexP hydrogel exhibited excellent intraocular biocompatibility and a safety profile. Overall, this carrier-free ADA@DexP hydrogel represents a promising alternative strategy for AU therapy, particularly given that both DexP and ADA are FDA-approved clinical agents.
  • ||||||||||  Remicade (infliximab) / J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / AbbVie
    Biomarker, Journal:  Distinct B Cell Subsets Changes as Potential Biomarkers of Response to Biologic Therapy in Crohn's Disease. (Pubmed Central) -  Oct 16, 2025   
    In contrast, for secukinumab, which has low immunogenicity, extending the dosing interval may lead to reduced serum drug levels and an increased risk of secondary failure. Our study suggests that infliximab/adalimumab induction therapy in CD expands circulating CD24hiCD27+ B cells and reduces mature na
  • ||||||||||  prednisone / Generic mfg., Humira (adalimumab) / AbbVie
    Journal:  Osseous Sarcoidosis of the Clivus Causing Cranial Nerve VI Palsy: A Case Report. (Pubmed Central) -  Oct 15, 2025   
    Although rare, sarcoidosis should be included in the differential diagnosis for patients with sterile, inflammatory bone lesions. Careful evaluation for additional clinical features of sarcoidosis and thorough histopathological evaluation of the bone biopsy for evidence of granulomatous inflammation, as well as exclusion of alternative etiologies of granulomatous disease, help distinguish these conditions.
  • ||||||||||  Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
    Review, Journal:  Severe liver injury due to infliximab therapy and adalimumab. (Pubmed Central) -  Oct 14, 2025   
    In contrast with the severe liver injury described in patients treated with infliximab, no cases of acute liver failure due to adalimumab requiring liver transplantation have been reported. However, subacute liver failure due to hepatitis B reactivation have been reported associated with adalimumab therapy and one case of subacute liver failure with adalimumab has been described in a patient without concomitant hepatitis B.
  • ||||||||||  Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
    Journal:  Evaluation of point-of-care instrument for quantification of infliximab and adalimumab. (Pubmed Central) -  Oct 13, 2025   
    We find the efficacy and accuracy of the ProciseDx acceptable, but when performed by non-laboratory personnel, the differences to routine measurements are considerable and could have a clinical impact. Clinical implementation would at least require reevaluation of the therapeutic intervals.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Retrospective data, Journal:  Trajectories of Adherence to Biologics in Patients With Inflammatory Bowel Diseases: A Large-Scale Multi-Regional Italian Study Through the VALORE Distributed Database. (Pubmed Central) -  Oct 10, 2025   
    Being female (odds ratio (OR) 1.52, 95% confidence interval (CI) 1.40-1.65), older (OR 1.44, 95% CI 1.21-1.70), and having adalimumab as index drug were each positively associated with low adherence compared to high adherence...Our findings highlight that one in three patients with IBDs gradually reduced adherence to biologics within the first 3?years of treatment. Differences were observed according to the initial biologic dispensed and patient characteristics such as sex and age, with females and older patients positively associated with low adherence.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  An Unusual Case of Fibromatous Fibrosis in a Young Hidradenitis Suppurativa Patient. (Pubmed Central) -  Oct 9, 2025   
    inhibitors, the complexity of managing concomitant keloids, and the need for vigilant monitoring and histological evaluation to differentiate benign from malignant conditions. A multidisciplinary approach is essential for optimal HS management, particularly in patients with atypical or treatment-resistant lesions.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Pyodermatitis-Pyostomatitis Vegetans with Eyelid Involvement: A Rare Manifestation in a Patient with Ulcerative Colitis. (Pubmed Central) -  Oct 9, 2025   
    The patient was successfully treated with Azathioporine and Adalimumab with significant improvement in gastrointestinal symptoms and mucocutaneous lesions after 3 months of therapy...Consideration of PDV-PSV as a mucocutaneous manifestation of UC is essential to avoid misdiagnoses and prevent unnecessary treatments. While periocular involvement may be rare, the presence of typical skin and oral lesions, along with distinctive histological and immunofluorescence findings, should guide clinicians toward the correct diagnosis.
  • ||||||||||  Clinical data, Review, Journal:  A targeted review of clinical outcomes of advanced IBD therapies in Latin America. (Pubmed Central) -  Oct 8, 2025   
    Advanced therapies for IBD appear to be effective in Latin American populations, with clinical outcomes comparable to those reported globally. Increasing access to these treatments may improve patient outcomes, reduce disease burden, and potentially decrease long-term healthcare costs in the region.
  • ||||||||||  methotrexate / Generic mfg., Humira (adalimumab) / AbbVie, azathioprine / Generic mfg.
    Journal:  Clinical and Ophthalmological Characteristics and Therapeutic Management of Patients With Sarcoidosis. (Pubmed Central) -  Oct 8, 2025   
    Systemic corticosteroids were the mainstay of treatment, with immunosuppressants and biologics reserved for refractory cases. Given the potential for asymptomatic ocular disease, routine ophthalmologic evaluation is recommended for all patients with sarcoidosis, regardless of the presence of ocular symptoms.